A research team led by neurobiologist Professor Claire Jacob has identified an important mechanism that can be used to control the restoration of myelin sheaths following traumatic injury and in degenerative diseases, such as multiple sclerosis. Their study is published in Nature Communications.

With the insights they have gained, the researchers were able to regenerate damaged myelin sheaths in mice by treating them with the active substance theophylline, thereby restoring their nerve cell function. The findings are the result of research carried out at Johannes Gutenberg University Mainz (JGU) and the University of Fribourg in Switzerland.

Neurons are composed of axons, ie, long fiber-like extensions that transmit signals to other cells. Many of them are surrounded by a myelin sheath, a thick fatty layer that protects them and helps to transfer stimuli rapidly. Without myelin, the functional capacity of neurons — and therefore of the whole nervous system — is limited and neurons can easily degenerate.

Multiple sclerosis (MS) is one of the diseases associated with myelin sheath degradation. MS patients suffer successive episodes of demyelination resulting in a progressive loss of function of their nervous system. Remyelination of the axons can prevent this, a media release from Johannes Gutenberg Universitaet Mainz explains.

Restoring the Myelin Coating is the Goal

Intact myelin sheaths are a prerequisite for the healthy functioning of the peripheral and central nervous systems. If the peripheral nervous system (PNS) is damaged — in an accident involving injury to the arms or legs, for example — the axons and their myelin sheaths can recover relatively well.

“Regeneration of the PNS is quite efficient, although it could be improved,” says Jacob, leader of the research team, pointing out that even young people do not experience complete regeneration.

However, the central nervous system (CNS) is completely different in this regard as there is no efficient restoration of the axons and therefore of the myelin sheath after a lesion. This means that CNS injuries usually result in permanent paralysis — as in the case of MS when loss of myelin leads to axon degeneration.

The occurrence of successive lesions can cause permanent loss of function of the CNS if myelin sheath restoration is inefficient. The capacity of the body to remyelinate decreases dramatically with age.

In their study, Jacob and her research group investigated how remyelination occurs in both peripheral and central nervous systems of mice.

“In order to promote the restoration of myelin, we need to understand the process that controls the mechanism. First, we wanted to understand the process that blocks remyelination. We subsequently studied how to counteract this blocking effect.”

— Claire Jacob

The neuroscientists identified a protein called eEF1A1 as a key factor in the process and found that eEF1A1 activated by acetylation prevents the remyelination process, but if eEF1A1 is deactivated by deacetylation, myelin sheaths can be rebuilt. The protein that deacetylates eEF1A1 is the enzyme called histone deacetylase 2 (HDAC2), the release continues.

Theophylline Promotes Myelin Reconstruction

“Once we understood this process, we decided to try to control it by boosting the HDAC2 activity and its synthesis in cells,” Jacob adds.

This was achieved by using the active substance theophylline, which is also present in tea leaves and has long been used in the treatment of asthma. In a mouse model, the use of theophylline over a period of four days resulted in significant recovery. Restoration of myelin sheaths was particularly impressive in the PNS, where they recovered completely.

Regeneration also improved in the CNS, as there was rapid and efficient rebuilding of myelin sheaths in both young and old mice. A low dose of the active substance was sufficient to trigger the improvements — a big plus with regard to the known side effects of theophylline, which occur at higher doses.

“In summary, this study […] shows that theophylline, by activating HDAC2, promotes eEF1A1 deacetylation, increases […] remyelination speed and efficiency after lesion of the PNS and CNS, thus appearing as a very promising compound to test in future translational studies to accelerate and promote remyelination after traumatic lesions or in the context of demyelinating disorders.”

–study authors, in Nature Communications

Currently, funding for corresponding clinical trials in patients is being sought, while a patent application has already been filed.

[Source(s): Johannes Gutenberg Universitaet Mainz, Science Daily]

Related Content:
Multiple Sclerosis Protection is Nuts
Multiple Sclerosis Treatment: Kessler Researchers Predict the Future
Spotlight Shines on microRNA for Treating Multiple Sclerosis